Recruiting
Observational
Platform for the Prospective Mother-child Study of the Determinants of Neurodevelopmental Disorders
Condition(s) studied
Autism Spectrum DisorderNeurodevelopmental Disorders
Investigational drug(s) / intervention(s)
QuestionnairesBiospecimen collectionNeurodevelopmental assessment visitDNA collection
Questionnaires: Parents will be asked to complete online self-questionnaires. These questionnaires will provide essential information on medical data, child development, lifestyle habits, nutritional habits, environmental exposures, and family social characteristics.
Biospecimen collection: urine, hair, nails, baby tooth, stool, blood, umbilical cord blood, placenta
Neurodevelopmental assessment visit: High-Risk Cohort : Clinical observations of the unborn child will be performed at 3 months, 6 months, 12 months, between 24 and 30 months, 36 months, and 72 months by psychologists or child psychiatrists in the participating hospitals. They will allow to evaluate the child's behaviors in the areas of communication and social interaction.
A video recording of the baby at 3 months of age will allow the analysis of the General Movements Assessment.
Low-Risk Cohort : linical observations of the unborn child will be performed at 72 months by psychologists or child psychiatrists in the participating hospitals.
DNA collection: If genetic consultation is provided to the family as part of the routine care, the results will be collected and additional blood samples may be taken.
Study summary
Neurodevelopmental disorders such as attention deficit disorder with or without hyperactivity, autism spectrum disorder, language and social communication disorder, motor coordination disorder, learning disorder (dyslexia, dyscalculia, dysorthography), intellectual development disorder are frequent and long-lasting developmental difficulties that can be observed in children in various domains. They are often associated and have a significant impact on daily functioning at school and at home.
The rate of people affected by neurodevelopmental disorders including autism spectrum disorder have increased significantly over the past 20 years. Improved screening only partly explains this evolution.
A genetic predisposition plays an important role in the occurrence of these disorders, however, current scientific data suggest a multifactorial origin. Exposures such as those related to the use of pesticides, air pollution or the presence of endocrine disruptors in our diet could be involved in the genesis of neurodevelopmental disorders, particularly during intrauterine life, a period of great vulnerability.
The current diagnostic pathways for autism rarely enable the early identification of babies at risk. Without early detection and timely targeted intervention, these children have a poor health outcome and do not reach their full potential.
The general objective of the MARIANNE cohort is to constitute a French research infrastructure dedicated to research on the biological and environmental determinants of neurodevelopmental disorders including autism.
This cohort is based on the follow-up of 1200 families with already a child affected by an autism spectrum disorder, which implies a high risk of neurodevelopmental disorders including autism spectrum disorder for the siblings, and of 500 families from the general population with no excess risk of neurodevelopmental disorders. The total number of subjects to be included (mother, father, unborn child and ASD sibling for the HR group) is thus 6300.
The inclusion of these families will be at the beginning of a new pregnancy and the follow-up will be carried out from the second trimester of pregnancy until the children are 6 years old, the age at which the diagnosis of neurodevelopmental disorders is possible.
Biological, clinical, social and environmental data will be collected at different stages of the follow-up and will be included into a large database.
Eligibility
INCLUSION CRITERIA:
General inclusion criteria (High risk and Low risk cohorts)
Mother:
* Be pregnant (single or multiple pregnancy), at least 16 weeks of amenorrhea,
* Have at least one biological child of 24 months or older,
* At least 18 years of age
Father:
* Be the biological father of the unborn child,
* At least 18 years of age
Unborn Child:
\- Have a woman study participant as mother.
Specific inclusion criteria for the High risk cohort:
* Autistic sibling: refers to the biological child(ren) of the mother and/or father participating in the study and being the parent(s) of the unborn child
* Be at least 24 months old and less than 18 years old,
* Have a confirmed diagnosis of Autism Spectrum Disorder based on medical records. If in doubt, the SRS-2 (Social Responsiveness Scale for Adults) and PEDS-DM (Parents' Evaluation of developmental status) questionnaires will be completed. Only children with positive scores on one of these questionnaires will be included after validation of the diagnosis by an expert committee,
* In case of several children with Autism Spectrum Disorder based in the siblings, only the last born will be included.
Remarks:
* Autism Spectrum Disorder siblings resulting from a medically assisted procreation are eligible provided that part of the genetic heritage is common to that of the mother or father of the unborn child participating in the study.
* If the father does not live with the mother of the unborn child, his participation is not required and does not preclude the participation of other family members.
EXCLUSION CRITERIA:
General non-inclusion criteria (High risk and Low risk cohorts):
Father and mother:
* Unable to understand French or the study questionnaires
* Participant on protective measures (guardianship or curatorship) or deprived of liberty by judicial or administrative decision, or subject to a legal protection measure
* Not affiliated to a social security system
* Refusal to participate. In the case of consent given for the born and unborn child, the consent must be given by the person(s) with parental authority.
* Live at a distance from the recruitment center incompatible with follow-up.
Specific non-inclusion criteria for the Low risk cohort:
Mother and/or father of unborn child:
\- Have a biological child with a diagnosis of Autism Spectrum Disorder or other neuro developmental disorder
Primary outcome measure(s)
- Autism Spectrum Disorder diagnosis — between 60 and 66 months
ASD diagnosis will be determined by the ADOS-2 (Autism Diagnostic Observation Schedule)
- Autism Spectrum Disorder diagnosis — between 24 and 30 months
ASD diagnosis will be determined by the ADOS-2 (Autism Diagnostic Observation
- Developmental Intelligence Disorder diagnosis — at 72 months
Measure of intelligence quotient by scales adapted to the child's age and level of development and developmental level: Weschler, or Mullen scales
- Developmental Coordination Disorder diagnosis — at 72 months
Description: the diagnosis will be determined by the DCDQ-FE (Developmental Coordination Disorder Parent Questionnaire Coordination), a 15 items scale, which is the French-European version of the DCDQ-0, Developmental Coordination Disorder Parent Questionnaire Coordination to help identify Developmental Coordination Disorder in children aged 5 to 15 years. The items are grouped into three subdomains: 1) control during movement, 2) fine motor/writing, and 3) global coordination. Each item is rated on a 5-point scale, from 1 ("does not match my child at all") to 5 ("matches my child perfectly")."
- Attention Deficit Hyperactivity Disorder diagnosis — at 72 months
The diagnosis will be determined by ADHD-RS, which is a parent questionnaire for the assessment of Attention Deficit Hyperactivity Disorder (ADHD). The items are rated on a 4-point scale (from 0= rarely or never, to 3= very often). A score greater than or equal to 28 is required to qualify as significant ADHD with this scale.
- Diagnosis of Language and Learning Disorder — at 72 months
the diagnosis will be determined with the Parents' Evaluation of developmental status (PEDS: DM), which targets the concerns of parents of children aged 0 to 8 years in 8 domains (gross and fine motor skills and writing and mathematics; social/emotional; oral/written language and reading; adaptive behavior).
This questionnaire has been validated in several countries and covers several domains, each with 6 to 8 questions and 3 answer choices. The results are evaluated as normal/delayed "Are you worried about your child's development? Yes/No" with details of the reasons, the age of onset and a question on the wish to have an interview with a psychologist or a child psychiatrist.
- Socioeconomic and lifestyle risk factors for neurodevelopmental disorders including autism spectrum disorder — at inclusion
Parental self-questionnaire
- Maternal diet and medication use during pregnancy — at inclusion
Parental self-questionnaire
- Environmental exposition — at inclusion
Parental self-questionnaire. A biological collection is realized for the realization of future assays
Trial sites (1)
| Facility | City | Region | Status |
|---|
| CHU Montpellier |
Montpellier |
France |
Recruiting |
More University Hospital, Montpellier trials in France
Other trials for the same condition
